Christian JungPartner at SV Health Investors
Christian joined the Dementia Discovery Fund (DDF) as a Partner in 2019 and currently represents the fund on the Boards of TranSINE Therapeutics and LoQus23. Prior to DDF, Christian was a Principal at Wellington Partners Life Sciences, where he was focused on investing in opportunities covering novel therapeutics and medical devices. Before joining Wellington, Christian was as a Senior Investment Manager with High-Tech Gründerfonds, Europe’s leading seed fund with € 896 million under management. There, Christian completed and led the investments in nine seed- and early-stage companies, including Amal Therapeutics SA (acquired by Boehringer Ingelheim in 2019 for up to € 325m), Cunesoft (acquired by Phlexglobla in 2020 for an undisclosed amount) and Rigontec GmbH (acquired by MSD in 2017 for up to € 464m). During the course of his PhD, Christian was supporting the Life Science Team of Atlas Venture in Munich.
Christian was awarded a PhD with distinction in Medical Science and Technology for his work on patient-specific induced pluripotent stem cells and obtained his MSc degree in Molecular Biotechnology, both from the Technical University of Munich. The key articles generated in the context of his PhD were published in the New England Journal of Medicine, EMBO Molecular Medicine and FASEB Journal and have so far been cited more than 1000 times. In 2013, the thesis was recognized with the “Outstanding PhD thesis award” by the Luxembourg National Research Fund.